James McKinnell, MD
Infectious Disease · Torrance, CANPI 1942403035
Payments from drug & device makers
Across 995 payments — averaging $4311.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$1.7M
- Genentech, Inc.$1.2M
- AbbVie$364K
- AstraZeneca$252K
- Aimmune Therapeutics, Inc.$248K
- Eli Lilly$238K
- plus $299K from 17 others
Across 6 payments — averaging $9330.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$52K
- F. Hoffmann-la Roche AG$4K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 20 | $1,654,785 |
| Genentech, Inc. | 27 | $1,233,621 |
| AbbVie(2 entities) | 566 | $363,776 |
| AstraZeneca(2 entities) | 18 | $252,075 |
| Aimmune Therapeutics, Inc. | 236 | $247,761 |
| Eli Lilly | 2 | $238,100 |
| Gilead | 7 | $99,707 |
| Remel, Inc. | 45 | $72,108 |
| Melinta Therapeutics, LLC | 16 | $70,992 |
| Roche Products Limited | 10 | $29,897 |
| Ferring Pharmaceuticals Inc. | 7 | $10,866 |
| Paratek Pharmaceuticals, Inc. | 9 | $5,412 |
| Tetraphase Pharmaceuticals, Inc. | 4 | $4,944 |
| Insmed, Inc. | 4 | $3,265 |
| Shionogi Inc | 3 | $1,201 |
| Accelerate Diagnostics Inc. | 4 | $613 |
| Biomerieux Inc | 3 | $143 |
| Astellas Pharma US Inc | 5 | $92 |
| Merck | 4 | $72 |
| Invivyd Inc | 1 | $36 |
| Mylan Specialty L.p. | 2 | $29 |
| La Jolla Pharmaceutical Company | 1 | $20 |
| Johnson & Johnson | 1 | $11 |
How this compares
$4,289,526 in reported general payments places this provider in the 95th percentile of 856 infectious disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in Torrance
- Loren MillerTorrance$4.1M
- Eric DaarTorrance$1M
- Peter RuaneLos Angeles$24.6M
- Raphael LandovitzLos Angeles$21.4M
- Philip RobinsonNewport Beach$4.9M
- Shawn HasslerSan Francisco$4.3M
- Jay GladsteinLos Angeles$4M
- Claire PomeroySacramento$3.8M
- Franco FelizartaBakersfield$3.5M
- Abhijit LimayeSan Francisco$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.